The financials
Integer Holdings Corporation by the numbers
Integer Holdings Corporation (ITGR) reported revenue of $440M in Q1 2026 (quarter ended April 3, 2026), up 0.5% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $17M (3.8% of revenue). For the full year FY2025, revenue was $1.85B (+8.0% year on year) and net income $103M. Its largest product in 2026-Q1 was Cardio And Vascular at $262M, 60% of the disclosed total, just ahead of Cardiac Rhythm Management Neuromodulation at 38%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $440M | $437M | +0.5% |
| Gross profit | $110M | $120M | −8.9% |
| Operating income | $32M | $50M | −36% |
| Net income | $17M | −$22M | to a profit |
| Diluted EPS | $0.48 | −$0.66 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Cardio And Vascular | $262M | 60% |
| Cardiac Rhythm Management Neuromodulation | $168M | 38% |
| Other Markets | $9.6M | 2.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $439.6M (-6.0%)
Cardiac Rhythm Management Neuromodulation grew +4.9% year on yearOther Markets -47% year on year
Segment Latestquarter on quarteryear on year
- Cardio And Vascular$261.7M$261.7MQoQ -5.6%year on year +1.1%-5.6%+1.1%
- Cardiac Rhythm Management Neuromodulation$168.3M$168.3MQoQ -0.53%year on year +4.9%-0.53%+4.9%
- Other Markets$9.6M$9.6MQoQ -55%year on year -47%-55%-47%